DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 06 · Volume 25 · December 2015 DOI: 10.1055/s-005-30053


Abstracts of the 29th Symposium of the AGNP
Munich, 23rd–26th September 2015

Chairs: Stefan Bleich, Hannover; Jens Wiltfang, Göttingen; Dirk Wedekind, Göttingen
Abstracts (HTML) List of Authors
  • A0
    Bleich, S; Wiltfang, J; Wedekind, D:

    Editorial/Opening Words

  • A1
    Adamovic, I; Sagebiel, A; Grohmann, R; Toto, S; Degner, D:

    Adverse drug reactions: vascular parkinsonism and sedation – a pharmacokinetic and pharmacodynamic evaluation from the German Pharmacovigilance project AMSP

  • A2
    Adamovic, I; Timäus, C; Klipper, T; Havemann-Reinecke, U:

    Stimulation of GABA-A (Diazepam) and GABA-B (Baclofen) receptor by a benzodiazepine depended patient: intoxication, clinic, treatment – a case report

  • A3
    Ambree, O; Ruland, C; Zwanzger, P; Arolt, V; Alferink, J:

    Altered myeloid and lymphoid immune cell responses following repeated social defeat stress

  • A4
    Böhr, S; Haen, E:

    Therapeutic drug monitoring of direct oral anticoagulants (DOAC)/UHPLC method for simultaneous determination of direct oral anticoagulants in human plasma

  • A5
    Bartz, J; Berger, C; Thome, J; Höppner, J:

    Psychomotor dysfunction in depression

  • A6
    Breitenstein, B; Scheuer, S; Brückl, T M; Meyer, J; Ising, M; Uhr, M; Holsboer, F:

    Optimizing antidepressant treatment dosage based on ABCB1 gene variants – Results from a randomized clinical study

  • A7
    Calzavara, E; Haen, E:

    Drug interactions in geriatic patients treated with venlafaxine

  • A8
    Curic, S; Thiebes, S; Polomac, N; Steinmann, S; Eichler, I; Eichler, L; Zöllner, C; Leicht, G; Mulert, C:

    Reduced early auditory evoked gamma-band response in ketamine model of schizophrenia

  • A9
    Elbau, I; Brücklmeier, B; Spoormaker, V; Binder, E; Czisch, M; Sämann, P G:

    Acute psychosocial stress investigated by an imaging stress test: concept and preliminary results

  • A10
    Elbau, I; Ising, M; Uhr, M; Schaaf, L; Holsboer, F; Lucae, S; Kloiber, S:

    Thyroid disorders are associated with impaired response to psychopharmacological treatment of major depression

  • A11
    Engler, L; Kuenzel, H; Riester, A; Dietz, A; Yassouridis, A; Reincke, M; Steiger, A:

    Differences in polysomnography between patients suffering from Connʼs syndrome in comparison with a control group

  • A12
    Esselmann, H; Hafermann, C; Jahn, O; Kraus, I; Vogelgsang, J; Haußmann, U; Uecker, M; Liepold, T; Klafki, H; Wiltfang, J:

    Analytical methods to explore Amyloid-β-Peptide variants beyond Aβ1-40 and Aβ1-42

  • A13
    Falter, T; Schmitt, V; Boeschen, S; Herold, S; Hefner, G; Weyer, V; Auer, C von; Lämmle, B; Rossmann, H; Scharrer, I; Lackner, K:

    Prevalence of Depression in patients with diagnosis of thrombotic thrombocytopenic purpura (TTP)

  • A14
    Fay, B; Seifert, J; Strueven, N T; Wenzel-Seifert, K; Haen, E:

    The sedative burden

  • A15
    Filiou, M D; Arefin, A S; Moscato, P; Graeber, M B:

    Alzheimerʼs disease, Parkinsonʼs disease and schizophrenia are not inflammatory diseases while inflammation is recognizable beyond organ borders

  • A16
    Filiou, M D; Webhofer, C; Guillermier, C; Poczatek, C; Wang, M; Turck, C W; Lechene, C P:

    Hippocampal protein turnover alterations in response to antidepressant treatment

  • A17
    Filiou, M D; Wood, P; Teplytska, L; Otte, D; Zimmer, A; Turck, C W:

    Altered myelination in schizophrenia: Evidence from animal models and human cohorts

  • A18
    Helm, S; Kleimann, A; Birkenstock, A; Schuppner, R; Bleich, S; Krüger, T; Kahl, K; Frieling, H:

    The use of ketamine in treatment-resistant major depression: a case study

  • A19
    Hennings, J M; Uhr, M; Klengel, T; Weber, P; Pütz, B; Touma, C; Czamara, D; Ising, M; Holsboer, F; Lucae, S:

    RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response

  • A20
    Hiebel, C; Kromm, T; Stark, M; Behl, C:

    Cannabinoid receptor 1 modulates the autophagic flux in a non-canonic fashion

  • A21
    Hohner, M; Hommers, L; Zebner, J; Deckert, J; Unterecker, S:

    QTc prolongation of amitriptyline and doxepin in relation to serum concentration and method of frequency correction

  • A22
    Hüttenrauch, M; Brauß, A; Kurdakova, A; Klafki, H; Wiltfang, J; Wirths, O:

    Physical activity ameliorates neuron loss and memory deficits in Tg4-42 mice

  • A23
    Ising, M; Zimmermann, P; Brückl, T; Pfister, H; Holsboer, F; Belcredi, P:

    Depression and burnout – Impact on sick leave and job satisfaction. Results from an epidemiological survey

  • A24
    Jahn, H; Denk, J:

    MicroRNA profiling of CSF in Alzheimerʼs disease

  • A25
    Jordan, K; Fromberger, P; Laubinger, H; Dechent, P; Müller, J L:

    Does the neural processing of visual sexual stimuli change under GnRH-therapy? A single case study in pedophilia

  • A26
    Karch, S; Keeser, D; Paolini, M; Hümmer, S; Konrad, J; Haller, D; Kirsch, V; Koller, G; Kupka, M; Blautzik, J; Pogarell, O:

    Real-time fMRI neurofeedback: application in patients with substance use disorder

  • A27
    Kraus, I; Kraus, I; Kraus, I; Besong-Agbo, D; Otto, M; Klafki, H; Klafki, H; Wiltfang, J; Wiltfang, J:

    Measurement of ERK1/2 Isoform distribution in peripheral blood mononuclear cells derived from whole blood from patients with different neuropsychiatric disorders

  • A28
    Kunath, N; Kumar, A; Dozier-Sharpe, M; Allison, D B; Van Groen, T; Kadish, I:

    Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimerʼs disease mouse model

  • A29
    Kunath, N; Müller, N; Tonon, M; Kopczak, A; Steiger, A; Dresler, M:

    Ghrelin does not act as a short-term cognitive enhancer in young male humans

  • A30
    Kunath, N; Müller, N; Tonon, M; Kopczak, A; Steiger, A; Dresler, M:

    Ghrelin does not act as a short-term cognitive enhancer in young male humans

  • A31
    Kundermann, B; Cabanel, N; Haag, A; Müller, M J:

    Chronotype and its relationship to sleep quality in patients with affective disorders and co-occurring insomnia

  • A32
    Kuzin, M; Lammertz, S E; Stegmann, B; Haen, E; Gründer, G; Paulzen, M:

    Effects of Proton Pump Inhibitors (PPI) on the serum concentrations of Venlafaxine

  • A33
    Lammertz, S E; Gründer, G; Tauber, S; Veselinovic, T; Hiemke, C; Paulzen, M:

    Concentrations of Venlafaxine, Mirtazapine and Citalopram in serum and cerebrospinal fluid – a naturalistic approach

  • A34
    Müller, M J; Cabanel, N; Haag, A; Olschinski, C; Kundermann, B:

    Chronotype distribution and stability in hospitalized patients with depression

  • A35
    Müller, M J; Netter, P; Haag, A; Kundermann, B:

    Salivary testosterone and cortisol response following mild controllable or uncontrollable laboratory stress in healthy males

  • A36
    Müller, M J; Rashid, D; Kundermann, B; Haag, A; Cabanel, N:

    Corrected qt time among patients treated with clozapine or quetiapine under clinical routine conditions

  • A37
    Mechler, K; Häge, A; Niemeyer, L; Schumm, L; Ben Dau, M; Dittmann, R W:

    Subjective experience and medication adherence in adolescents with psychiatric disorders – preliminary findings from the Mannheim SEMA study

  • A38
    Hüttenrauch, M; Brauß, A; Kurdakova, A; Klafki, H; Wiltfang, J; Wirths, O:

    Physical activity ameliorates neuron loss and memory deficits in Tg4-42 mice

  • A39
    Mikoteit, T; Beck, J; Hemmeter, U; Brand, S; Bischof, R; Delini-Stula, A; Holsboer-Trachsler, E; Eckert, A:

    Assessment of serum levels of mature brain-derived neurotrophic factor (mBDNF) is not superior to total (tot)BDNF in prediction of antidepressant treatment outcome

  • A40
    Mikoteit, T; Brand, S; Bürki, N; Hösli, I; Holsboer-Trachsler, E:

    Breastfeeding is associated with increased Non REM S3-sleep in non-depressive mothers three months post partum

  • A41
    Chechko, N; Kellermann, T; Habel, U:

    Brain circuitries involved in emotional interference task in major depression and borderline personality disorders

  • A42
    Ben Omar, N; Haen, E:

    Quantification of Eighteen Psychotherapeutic Agents and their metabolites Using Column Switching HPLC/UV

  • A43
    Nussbaumer, M; Asara, J M; Teplytska, L; Murphy, M P; Landgraf, R; Turck, C W; Filiou, M D:

    Mitochondria as pharmacological targets for anxiolytic treatment

  • A44
    Paulus, W E:

    Pregnancy outcome after use of zopiclone during first trimester

  • A45
    Paulzen, M; Gründer, G; Veselinovic, T; Wolf, B; Hiemke, C; Lammertz, S:

    Duloxetine enters the brain – but why is it not found in the cerebrospinal fluid

  • A46
    Paulzen, M; Lammertz, S E; Veselinovic, T; Goecke, T; Hiemke, C; Gründer, G:

    Psychopharmacotherapy during pregnancy: Therapeutic drug monitoring (TDM) in maternal blood, amniotic fluid and umbilical cord blood

  • A47
    Koo, P C; Berger, C; Bartz, J; Wybitul, P; Thome, J; Hoeppner, J:

    Relationship between dynamic neural activities and clinical symptoms in depression

  • A48
    Rampp, C; Eichelkraut, A; Best, J; Uhr, M; Binder, E B; Menke, A:

    Gender related differential response to dexamethasone in endocrine and immune measures in depressed patients and healthy controls

  • A49
    Richter, A; Petrovic, A; Diekhof, E K; Trost, S; Wolter, S; Gruber, O:

    Hyperresponsivity and impaired prefrontal control of the mesolimbic reward system in schizophrenia

  • A50
    Rothammer, C; Haen, E:

    Development of a method to determine caffeine in human serum by HPLC

  • A51
    Sadeghi Bahmani, D; Farnia, V; Hojatitabar, S; Shakeri, J; Rezaei, M; Yazdchi, K; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    Adjuvant Rosa damascena has a small effect on SSRI-induced sexual dysfunction in female patients suffering from MDD

  • A52
    Sadeghi Bahmani, D; Farnia, V; Shakeri, J; Yazdchi, K; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    The comparison of the effect of yoga and aquatic exercises on depression and fatigue in patients with multiple sclerosis

  • A53
    Sämann, P; Elbau, I; Höhn, D; Schmaal, L; Czisch, M:

    Hippocampal subfield analysis to compare the depression and neurodegeneration spectrum

  • A54
    Sämann, P; Gruber, O; Czisch, M:

    Impact of vigilance fluctuations on resting state fMRI functional connectivity analysis

  • A55
    Sämann, P; Zannas, A; Carrillo, T; Binder, E:

    Structural MR correlates of epigenetic age acceleration

  • A56
    Schuster, R; Koopmann, A; Kiefer, F:

    Calcium for the treatment of alcohol-dependence

  • A57
    Stepan, J; Micale, V; Wotjak, C T; Eder, M:

    Enhanced endocannabinoid signaling boosts signal propagation through the hippocampal trisynaptic circuit and facilitates safety learning

  • A58
    Stratmann, M; Sommer, J; Belke, M; Knake, S; Kircher, T; Konrad, C:

    Manual and automated segmentation of the human hippocampus in cerebral magnetic resonance images

  • A59
    Stropahl, U; Köhler, H; Möckel, G; Braunroth, J; Wandschneider, R; Thome, J:

    Pregnancy and antipsychotics

  • A60
    Thiebes, S; Curic, S; Polomac, N; Feroz, F; Steinmann, S; Eichler, L; Eichler, I; Zöllner, C; Leicht, G; Mulert, C:

    The effects of glutamatergic modulation on human auditory perception and behavioural changes in a Mismatch Negativity (MMN) paradigm

  • A61
    Unholzer, S; Wolf, M; Köppl, A; Haen, E:

    Bipolar disorder: Development of an UHPLC-UV method for the determination of 8 psychiatric drugs in human serum

  • A62
    Veselinovic, T; Vernaleken, I B; Janouschek, H; Paulzen, M; Gründer, G:

    Realationship between dopamine D2 receptor availability and cognitive performance and psychopathology in drug-free patients with schizophrenia

  • A63
    Vogelgsang, J; Wiltfang, J; Masliah, E; Winkler, J; Klucken, J:

    Dopaminergic stimulation in a transgenic model of neurodegeneration restores decreased proliferation and viability in subventricular zone derived adult neural precursor cells

  • A64
    Warrings, B; Deckert, J; Unterecker, S:

    Association between body weight and serum concentration of antidepressant drugs

  • A65
    Wolf, L; Bauer, A; Melchner, D; Hallof-Buestrich, H; Stoertebecker, P; Haen, E; Kreutz, M; Sarubin, N; Milenkovic, V M; Wetzel, C H; Rupprecht, R; Nothdurfter, C:

    Enhancing neurosteroid synthesis – Relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines

  • A66
    Wrosch, J; Beckmann, D; Kornhuber, J; Groemer, T W:

    The effects of antipsychotic drugs on primary hippocampal networks developing under different electrical stimulation patterns

  • A67
    Zeise, M; Morales, B; Rozas, C; Burgos, H; Hernández, A:

    Psychostimulants and metaplasticity

  • A68
    Chrobok, A; Länger, A; Karch, S; Keeser, D; Lehmann, K; Leicht, G; Mulert, C; Eser-Valeri, D; Ertl-Wagner, B; Dieterich, M; Rupprecht, R; Pogarell, O:

    Anticipatory anxiety in phobic postural vertigo patients – functional indicators for anxiety-related disorder

  • A69
    Cohrs, S; Goerke, M; Rodenbeck, A; Riemann, D; Wiedemann, K; Thome, J; Winterer, G; Kiefer, F:

    Decreased plasma orexin levels in subjects with impaired sleep quality

  • A70
    Cohrs, S; Pülschen, D; Goerke, M; Thome, J; Schlack, R:

    Vitamin D and its relation to sleep disturbance and depressive symptomatology – Results of the German Health Interview and examination survey for adults

  • A71
    Curic, S; Thiebes, S; Polomac, N; Steinmann, S; Eichler, I; Eichler, L; Zöllner, C; Leicht, G; Mulert, C:

    Reduced early auditory evoked gamma-band response in ketamine model of schizophrenia

  • A72
    Elbau, I; Ising, M; Uhr, M; Schaaf, L; Holsboer, F; Lucae, S; Kloiber, S:

    Thyroid disorders are associated with impaired response to psychopharmacological treatment of major depression

  • A73
    Falter, T; Schmitt, V; Boeschen, S; Herold, S; Hefner, G; Weyer, V; Auer, C von; Lämmle, B; Rossmann, H; Scharrer, I; Lackner, K:

    Prevalence of depression in patients with diagnosis of thrombotic thrombocytopenic purpura (TTP)

  • A74
    Hennings, J M; Uhr, M; Klengel, T; Weber, P; Pütz, B; Touma, C; Czamara, D; Ising, M; Holsboer, F; Lucae, S:

    RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response

  • A75
    Hensch, T; Sander, C; Wozniak, D; Glass, J; Mauche, N; Spada, J; Jawinski, P; Hegerl, U:

    Biological correlates of hypomanic personality: genetics, sleep and brain arousal

  • A76
    Jahn, H; Denk, J:

    MicroRNA profiling of CSF in Alzheimerʼs disease

  • A77
    Karch, S; Keeser, D; Paolini, M; Hümmer, S; Konrad, J; Haller, D; Kirsch, V; Koller, G; Kupka, M; Blautzik, J; Pogarell, O:

    Real-time fMRI neurofeedback: application in patients with substance use disorder

  • A78
    Mauche, N; Sander, C; Jawinski, P; Enzenbach, C; Schönknecht, P; Hegerl, U; Hensch, T:

    Impact of chronic smoking on P3 components in a three-stimulus oddball paradigm

  • A79
    Meyer-Roetz, S H; Scherbaum, N; Wiltfang, J; Benninghoff, J:

    Effects of the psychopharmacological treatment by an outpatient clinic by patients living in nursing homes

  • A80
    Mueller-Siecheneder, F:

    Diagnosing and managing anticholnergic side effects in psychopharmcological treatments

  • A81
    Chechko, N; Kellermann, T; Habel, U:

    Brain circuitries involved in emotional interference task in major depression and borderline personality disorders

  • A82
    Neitzert, K; Albayram, Ö; Ambrée, O; Lundt, R; Karaca, I; Cron, M; Müller, C; Förster, I; Bilkei, A; Gorzo, A; Jessen, F; Walter, J; Scheu, S; Maier, W; Zimmer, A; Alferink, J:

    CCL17-deficiency alters myeloid cell-responses and prevents cognitive decline in APP/PS1-mice

  • A83
    Nussbaumer, M; Asara, J M; Teplytska, L; Murphy, M P; Landgraf, R; Turck, C W; Filiou, M D:

    Mitochondria as pharmacological targets for anxiolytic treatment

  • A84
    Paulus, W E:

    Pregnancy outcome after use of zopiclone during first trimester

  • A85
    Paulzen, M; Lammertz, S E; Veselinovic, T; Goecke, T; Hiemke, C; Gründer, G:

    Psychopharmacotherapy during pregnancy: Therapeutic drug monitoring (tdm) in maternal blood, amniotic fluid and umbilical cord blood

  • A86
    Pogarell, O; Karch, S; Dunkel, G; Segmiller, F; Engelbregt, H; Keeser, D:

    Resting state EEG and functional connectivity in patients with major depression and under electro-convulsive therapy

  • A87
    Rossner, M; Hasan, A; Falkai, P; Klebl, B; Wehr, M:

    Building academic-industrial alliances to stimulate drug discovery for psychiatric diseases

  • A88
    Ruland, T; Domschke, K; Schütte, V; Zavorotnyy, M; Kugel, H; Notzon, S; Vennewald, N; Ohrmann, P; Arolt, V; Pfleiderer, B; Zwanzger, P:

    Neuropeptide S receptor gene variation modulates glutamatergic anterior cingulate cortex activity during CCK-4 induced panic

  • A89
    Sadeghi Bahmani, D; Farnia, V; Hojatitabar, S; Shakeri, J; Rezaei, M; Yazdchi, K; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    Adjuvant Rosa damascena has a small effect on SSRI-induced sexual dysfunction in female patients suffering from MDD

  • A90
    Sadeghi Bahmani, D; Farnia, V; Shakeri, J; Yazdchi, K; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    The comparison of the effect of yoga and aquatic exercises on depression and fatigue in patients with multiple sclerosis

  • A91
    Sadeghi Bahmani, D; Jahangard, L; Akbarian, S; Haghighi, M; Ahmadpanah, M; Keshavarzi, A; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    Children suffering from ADHD improved in behavior when treated with methylphenidate and adjuvant risperidone, compared to methylphenidate only, though weight gain was also observed – results from a randomized, double-blind, placebo-controlled clinical trial

  • A92
    Sadeghi Bahmani, D; Shayganfard, M; Haghighi, M; Ahmadpanah, M; Pirdehghan, A; Bajoghli, H; Holsboer-Trachsler, E; Brand, S:

    Repetitive Transcranial Magnetic Stimulation (rTMS) improves symptoms and reduces clinical illness in patients suffering from OCD – Results from a single-blind, randomized clinical trial with sham cross-over condition

  • A93
    Sämann, P; Elbau, I; Höhn, D; Schmaal, L; Czisch, M:

    Hippocampal subfield analysis to compare the depression and neurodegeneration spectrum

  • A94
    Sämann, P; Gruber, O; Czisch, M:

    Impact of vigilance fluctuations on resting state fMRI functional connectivity analysis

  • A95
    Sämann, P; Zannas, A; Carrillo, T; Binder, E:

    Structural MR correlates of epigenetic age acceleration

  • A96
    Schmidt, F M; Sander, C; Dietz, M E; Nowak, C; Schröder, T; Himmerich, H; Schönknecht, P; Hegerl, U:

    EEG-measured vigilance regulation as response predictor for antidepressant therapy in major depression (VIRAP)

  • A97
    Stepan, J; Micale, V; Wotjak, C T; Eder, M:

    Enhanced endocannabinoid signaling boosts signal propagation through the hippocampal trisynaptic circuit and facilitates safety learning

  • A98
    Strauss, M; Paucke, M; Sander, C; Hegerl, U:

    Vigilance regulation in adult ADHD

  • A99
    Zeise, M; Burgos, H; Cofré, C; Hernández, A; Saez, P; Morales, B:

    Methylphenidate induces long-lasting changes in synaptic plasticity after repetitive administration in adolescent rats

  • A100
    Zeise, M; Morales, B; Rozas, C; Burgos, H; Hernández, A:

    Psychostimulants and metaplasticity

  • A101
    Vogelgsang, J; Wiltfang, J; Masliah, E; Winkler, J; Klucken, J:

    Dopaminergic stimulation in a transgenic model of neurodegeneration restores decreased proliferation and viability in subventricular zone derived adult neural precursor cells

  • A102
    Zilles, D; Folsche, T:

    Case report: Effectiveness of inhalative loxapin in the treatment of therapy refractory agitation

  • A103
    Mavridou, K; Wiltfang, J:

    Clozapine for the treatment-resistant symptoms of derealisation and obsessive ruminations – A clinical case report

  • A104
    Antonios, G; Borgers, H; Pilot, T; Pena, V; Bayer, T A:

    NT4X-167; Novel N-terminal Aβ specific antibody, prevents in vitro and in vivo toxicity of highly toxic Aβ4-42 species

  • A105
    Richter, A; Petrovic, A; Diekhof, E; Trost, S; Wolter, S; Gruber, O:

    Hyperresponsivity and impaired prefrontal control of the mesolimbic reward system in schizophrenia

  • A106
    Goya-Maldonado, R; Brodmann, K; Keil, M; Trost, S; Dechent, P; Gruber, O:

    Network fingerprints to distinguish bipolar and unipolar depression by fMRI

  • A107
    Wedekind, D:

    Plasma tryptophan and clinical phenotypes in alcohol addicted males during acute tryptophan depletion depend on 5HTTPR-polymorphism

  • A108
    Wedekind, D; Havemann-Reinecke, U:

    Disulfiram and relapse-prevention in alcohol addiction

  • A109
    Warrings, B; Deckert, J; Unterecker, S:

    Association between body weight and serum concentration of antidepressant drugs

  • A110
    Riedel, C; Broich, K; Escherich, A; Sudhop, T; Fritze, J:

    Evaluation of the extend of off-label use among the most common prescribed medicinal products based on data of the Statutory health insurance system in Germany – Design of the Evaluation

  • A111
    Kraus, I; Besong Agbo, D; Otto, M; Klafki, H; Wiltfang, J:

    Measurement of ERK1/2 isoform distribution in peripheral blood mononuclear cells derived from whole blood from patients with different neuropsychiatric disorders